Comparison of Vascular Catheter-Related Thrombosis and Risk Factors After Oncologic and Non-Oncologic Major Surgery
Launched by MERSIN UNIVERSITY · Oct 9, 2024
Trial Information
Current as of November 13, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is looking at the risk of blood clots related to vascular catheters used during major surgeries, both for cancer and non-cancer patients. Researchers want to understand how common these clots are and what factors might increase the risk. They will use daily ultrasound exams to monitor patients after their surgeries.
To be eligible for this study, participants need to be adults aged 18 to 80 who do not have blood disorders that make them more likely to develop clots. They also should not be on blood-thinning medications and must have no signs of existing blood clots before their catheter is placed. The study is currently recruiting participants, and those who join can expect to have regular ultrasound checks to ensure their safety during recovery. This study aims to improve our understanding of blood clot risks, which can help in providing better care for patients undergoing major surgeries.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Adult patient (18-80 years old)
- • No hematological disease causing hypercoagulability
- • Not receiving anticoagulant/antifibrinolytic medications at the therapy dose
- • The vascular structure can be visualized with US
- • No thrombosis in the US control before catheter placement
- • The catheter is not inserted for renal replacement therapy
- Exclusion Criteria:
- • Presence of renal failure
- • Pediatric patients
- • Presence of hematological malignancy
- • Inadequate US imaging
About Mersin University
Mersin University is a distinguished academic institution located in Mersin, Turkey, committed to advancing healthcare through innovative research and clinical trials. With a strong emphasis on interdisciplinary collaboration, the university leverages its extensive resources, expert faculty, and state-of-the-art facilities to facilitate groundbreaking studies. Mersin University aims to contribute to the global medical community by fostering the development of new therapies and improving patient outcomes through rigorous scientific inquiry and ethical standards in clinical research.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Mersin, Turkey
Mersin, Yenişehir, Turkey
Patients applied
Trial Officials
Levent Özdemir
Principal Investigator
Mersin University, Faculty of Medicine, Mersin, Turkiye
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported